| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Alcon Inc.$67.81
+0.67 (+1%)
B 68Pipeline Score MedTech · Commercial
Market Cap
32.12 B
EPS
1.67
P/E Ratio
38.65 $
Value Trade
165.52 M
5.04 %
Week
-12.72 %
1 Month
-18.38 %
3 Month
-10.12 %
6 Month
-1.57 %
5 Year
16.96 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
1.69 M
52 Week Range
61.84 - 92.55
% held by Insiders
1.23 %
% held by Institutions
52.77 %
Enterprise Value
35.74 B
Total Shares
487.40 M
Short %
1.79 %
Float Shares
481.40 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alcon Inc.
341Total events
1Upcoming
142Tier-1 (high impact)
2002 – 2026Coverage
Upcoming catalysts 1
Event history 340
Jul 6, 2026
▲Partnership / LicenseCorporate
Alcon and RxSight announce collaboration to develop adjustable PCIOLs
cataract surgerysource ↗
Jul 6, 2026
▲Milestone PaymentCorporate
RxSight receives $60 million upfront payment from Alcon
cataract surgerysource ↗
Jun 15, 2026
Feb 17, 2026
▲Product LaunchTOTAL30Post-Market
U.S. launch of TOTAL30 Multifocal for Astigmatism
presbyopia with astigmatismsource ↗
Feb 2, 2026
▲Product LaunchPRECISION7Post-Market
Canadian launch of PRECISION7 sphere and toric contact lenses
refractive errorsource ↗
2026
▲Product LaunchTOTAL30Post-Market
International launch in limited markets in 2026
presbyopia with astigmatismsource ↗
2022
●Quarterly UpdateCorporate
Aerie full year 2022 net product revenue guidance $130-140 million
Apr 28, 2021
▲Partnership / LicenseSimbrinzaCorporate
Alcon signs agreement to acquire exclusive U.S. commercialization rights to Simbrinza from Novartis
open-angle glaucoma or ocular hypertensionsource ↗
Apr 28, 2021
▲Product LaunchPost-Market
U.S. launch of Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops
dry eyesource ↗
Drug Pipeline Intelligence
B68
Pipeline Score $17.6B
Pipeline ValueValuation Signal
68
Drugs Scored1.8x
rNPV / MCap Top 93%
Mid Cap (rank 65 of 911)
Percentile RankAlcon Inc. holds a solid B-grade pipeline (68/100), with $20.8B risk-adjusted pipeline value, led by Moxidex otic in Acute Otitis Media (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Moxidex otic Small molecule | Acute Otitis Media | Phase 3 | NCT00578773 | 58% | $1.8B | COMPLETED | 1,990 | - | - | Jan 1, 2009 | - | Dec 3, 2012 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ALLEGRETTO WAVE Eye-Q | LASIK surgery | — | 2009-03-10 | Results demonstrated excellent clinical outcomes on the ALLEGRETTO WAVE Eye-Q Read More | Alcon Signs Contract with LCA-Vision for 75 ALLEGRETTO WAVE Excimer Lasers LASIK chain standardizes with high-end technology based on study results. Read More | |
ALLEGRETTO WAVE Eye-Q | LASIK surgery | — | 2009-03-10 | Results demonstrated excellent clinical outcomes on the ALLEGRETTO WAVE Eye-Q Read More | Alcon Signs Contract with LCA-Vision for 75 ALLEGRETTO WAVE Excimer Lasers LASIK chain standardizes with high-end technology based on study results. Read More | |
ALLEGRETTO WAVE Eye-Q | LASIK surgery | — | 2009-03-10 | Results demonstrated excellent clinical outcomes on the ALLEGRETTO WAVE Eye-Q Read More | Alcon Signs Contract with LCA-Vision for 75 ALLEGRETTO WAVE Excimer Lasers LASIK chain standardizes with high-end technology based on study results. Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ALC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ALC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ALCAlcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
Alcon and RxSight have entered a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). This partnership aims to combine Alcon's optical designs with RxSight's light-adjustable technology, allowing surgeons to fine-tune visual outcomes post-cataract surgery. RxSight will receive an upfront payment of $60 million, with potential additional payments tied to development milestones.
Read more →ALCAlcon lance UNITYMD CS au Congrès de la SCO 2026, qui marque une avancée majeure dans la prochaine génération d’innovations chirurgicales au Canada
Alcon has unveiled its UNITYMD CS at the SCO 2026 Congress, marking a significant step forward in surgical innovations in Canada. This launch emphasizes the company's dedication to advancing surgical technologies. The event serves as a platform for showcasing these new innovations to the medical community.
Read more →ALCAlcon Launches UNITY® CS at COS 2026, Advancing the Next Generation of Surgical Innovation in Canada
Alcon has launched its UNITY® CS system at the COS 2026 conference, marking a significant advancement in surgical technology. This innovative system is designed to improve surgical outcomes and reflects Alcon's dedication to enhancing surgical practices in Canada. The introduction of this product is expected to set new standards in the field.
Read more →ALCAlcon Announces Results of 2026 Annual General Meeting
Alcon Inc. successfully held its 2026 Annual General Meeting, where shareholders approved all proposed resolutions. Key board members, including Chair F. Michael Ball, were re-elected, and a gross dividend of CHF 0.28 per share was declared. The meeting also included the approval of financial statements and the re-election of statutory auditors.
Read more →ALCAlcon Launches TOTAL30 Multifocal for Astigmatism, the World’s Only Monthly Multifocal Toric Contact Lens with Water Gradient Technology
Alcon has launched the TOTAL30 Multifocal for Astigmatism, the first multifocal toric contact lens featuring Water Gradient Technology. This innovation aims to provide enhanced comfort and clear vision for presbyopic patients with astigmatism. The lenses are now available in the U.S. and will be introduced in select international markets by 2026.
Read more →ALCAlcon Debuts Groundbreaking PRECISION7 in Canada, a One-Week Replacement Contact Lens to Start and End Every Week Fresh
Alcon has announced the launch of PRECISION7, a one-week replacement contact lens featuring the ACTIV-FLO System, in Canada. This innovative lens offers 16 hours of comfort and precise vision, even on day 7. Available from February 2026, it aims to improve patient compliance and experience by providing a more intuitive replacement schedule compared to traditional options.
Read more →ALCCOMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio Builds on Alcon's existing commercial expertise in the estimated $20 bi
MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio Ad hoc announcement pursuant to Art. 53 LR GENEVA, Switzerland and DURHAM, NC August 22, 2022 - Alcon (SIX/NYSE: ALC), the globa
Read more →ALCDocument Alcon Announces Executive Committee Changes Geneva
Alcon Announces Executive Committee Changes Geneva, June 28, 2021 - Alcon (SIX NYSE ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced changes to its Executive Committee of Alcon (ECA). Changes take effect September 1, 2021. Ian Bel
Read more →ALCDocument Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza Expands Alcon's existing portfolio and strengthens position in the ophthalmic eye drops market Builds on company's ophthalmic pharm
Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza Expands Alcon's existing portfolio and strengthens position in the ophthalmic eye drops market Builds on company's ophthalmic pharmaceutical manufacturing expertise Geneva, April 28, 2021 - Alcon (
Read more →ALCGLOSSY PAGES TO ANNUAL REPORT Exhibit 1 | Alcon Annual Report 2019 2 | Alcon Annual Report 2019 Dear Shareholder, In 1945, two pharmacists in Fort Worth, Texas, Robert Alexander and William Conner, started a company that
1 | Alcon Annual Report 2019 2 | Alcon Annual Report 2019 ii | Alcon Annual Report 2019 I am proud of what our team has accomplished following spin-off, particularly in the areas of standing up the new company, accelerating our innovation pipeline to grow revenue, and develop
Read more →ALCCOMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Alcon Introduces AcrySof IQ PanOptix Trifocal IOL in the U.S., the First and Only FDA-Approved Trifocal Lens PanOptix delivers an exceptional combination of near, inte
AUX MEDIAS MEDIENMITTEILUNG AcrySof IQ PanOptix Trifocal IOL in the U.S., the First and Only FDA-Approved Trifocal Lens August 27, 2019 - Alcon (SIX/NYSE:ALC), the global leader in eye care, today announced the Food and Drug Administration (FDA) approval and its initial commer
Read more →ALCAlcon Reports First Quarter 2019 Trading Update First quarter sales of $1.8 billion, flat to last year; an increase of 4% constant currency (cc) Healthy momentum in Surgical business, with 2% growth and 7% constant curre
Alcon Reports First Quarter 2019 Trading Update First quarter sales of $1.8 billion, flat to last year; an increase of 4% constant currency (cc) Healthy momentum in Surgical business, with 2% growth and 7% constant currency growth Full year 2019 outlook of 3% to 5% constant cu
Read more →ALCAPRIL 2019 NOVARTIS AG ALCON INC. SEPARATION AND DISTRIBUTION AGREEMENT CONTENTS Clause Page 1. THE SEPARATION 3 2. THE ALCON TRANSFERRING ASSETS 5 3. THE NOVARTIS TRANSFERRING ASSETS 7 4. LOCAL SEPARATION AGREEMENTS 8 5
SEPARATION AND DISTRIBUTION AGREEMENT Clause Page 1. THE SEPARATION 3 2. THE ALCON TRANSFERRING ASSETS 5 3. THE NOVARTIS TRANSFERRING ASSETS 7 4. LOCAL SEPARATION AGREEMENTS 8 5. THE DISTRIBUTION 9 6. GLOBAL CONDITIONS 10 7. BRAZIL 12 8. TRANSFERRING CONTRACTS 12 9. MA
Read more →ALCSouth Freeway Fort Worth, Texas 76134-2099 http://www.alcon.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Alcon Announces Timothy Stonesifer as Chief Financial Officer Fort Worth, Texas
MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Alcon Announces Timothy Stonesifer as Chief Financial Officer Fort Worth, Texas, April 2, 2019 Alcon, the global leader in eye care and a division of Novartis, announced today that Timothy C. Stonesifer ( Tim ) will join the
Read more →ALCAlcon Shareholders Approve Merger with Novartis
Alcon Shareholders Approve Merger with Novartis HUENENBERG, Switzerland - April 7, 2011 - Alcon, Inc. (NYSE:ACL) announced that its shareholders approved the merger of Alcon into Novartis AG at its Annual General Meeting of Shareholders. Under the terms of the merger, Alcon shar
Read more →ALCAlcon Continuing Our Vision 2010 Annual Report Alcon is dedicated to discovering, developing, producing and marketing high-quality eye care products that enhance, preserve and restore sight globally. We serve the world's
Alcon Continuing Our Vision 2010 Annual Report Alcon is dedicated to discovering, developing, producing and marketing high-quality eye care products that enhance, preserve and restore sight globally. We serve the world's eye care needs with a broad portfolio of market-leading su
Read more →ALCAlcon Announces Date of Annual General Meeting
Alcon Announces Date of Annual General Meeting HUENENBERG, Switzerland, February 28, 2011 - Alcon, Inc. (NYSE:ACL) announced today that it will hold its Annual General Meeting of shareholders on April 7, 2011. The company will hold the meeting at 3:30 p.m. Central European Time
Read more →ALCALCON, INC. B sch 69 P.O. Box 62 H nenberg, Switzerland 2010 Business Report 2 ALCON, INC. 2010 Business Report Table of Contents Page Reference Management's Report on Internal Control over Financial Reporting 5 Reports
H nenberg, Switzerland 2010 Business Report 2010 Business Report Page Reference Management's Report on Internal Control over Financial Reporting 5 Reports of Independent Registered Public Accounting Firm 6 Consolidated Balance Sheets 8 Consolidated Statements of Earnings 9 Co
Read more →ALCStatuten der Alcon, Inc. vom 20. Januar 2011 Articles of Association of Alcon, Inc. as of
Articles of Association of as of January 20, 2011 Abschnitt 1: Firma, Sitz, Zweck und Dauer der Gesellschaft Section 1: Name, Place of Incorporation, Purpose and Duration Firma, Sitz Artikel 1 Unter der Firma Alcon, Inc. besteht eine Aktiengesellschaft mit Sitz in H
Read more →ALCAlcon and Novartis Agree to Merger Terms Novartis to pay total merger consideration valued at $168 per share, through a combination of Novartis shares and a contingent value cash component Deal to be executed under Swiss
Alcon and Novartis Agree to Merger Terms HUENENBERG, Switzerland - December 15, 2010 - Alcon, Inc. (NYSE: ACL) announced today that its board of directors approved a merger agreement with Novartis AG, whereby Novartis will pay a total merger consideration valued at $168 per shar
Read more →ALCMerger Agreement Of
Merger Agreement Of December 14, 2010 Between Novartis AG Company Number CH-270.3.002.061-2 Lichtstrasse 35 CH-4056 Basel Switzerland a company limited by shares ( Aktiengesellschaft ) pursuant to art. 620 ff. CO having its seat in Basel (hereinafter " Novartis ") And Alcon,
Read more →ALCAlcon Board Elects New Chairman Dr. Daniel Vasella elected chairman Cary Rayment will serve as vice-chairman H U
Alcon Board Elects New Chairman HUENENBERG, Switzerland - October 24, 2010 - The Alcon, Inc. (NYSE:ACL) board of directors elected Dr. Daniel Vasella as its chairman of the board, replacing Cary Rayment who had served as chairman since May 3, 2005. Dr. Vasella is also chairman o
Read more →ALCAlcon Independent Director Committee Notes Change in Alcon Chairmanship o No Change in Composition or Mandate of the IDC o Novartis' Merger Proposal Cannot Be Approved by the Alcon Board Without Prior Recommendation by t
Alcon Independent Director Committee Notes Change in Alcon Chairmanship HUENENBERG, Switzerland - October 24, 2010 - The Alcon Independent Director Committee (the "IDC") notes that Dr. Daniel Vasella, Chairman of Novartis AG ("Novartis"), replaced Mr. Cary Rayment as Chairman of
Read more →ALCAlcon, Inc. Slides used during the Alcon, Inc. conference call
Alcon, Inc. Slides used during the Alcon, Inc. conference call October 21, 2010
Read more →ALCAlcon Introduces New Systane BALANCE Lubricant Eye Drops for Dry Eye Patients with Meibomian Gland Dysfunction
Alcon Introduces New Systane BALANCE Lubricant Eye Drops for Dry Eye Patients with Meibomian Gland Dysfunction HUENENBERG, Switzerland - October 11, 2010 - Alcon, Inc. (NYSE: ACL), the world's leader in eye care, announced the launch of Systane BALANCE Lubricant Eye Drops, the n
Read more →ALCAlcon Names New Chief Financial Officer
Alcon Names New Chief Financial Officer HUENENBERG, Switzerland - October 4, 2010- Alcon, Inc. (NYSE: ACL) announced today the appointment of Robert Karsunky as senior vice president and chief financial officer effective November 1, 2010. Karsunky comes to Alcon from Novartis AG
Read more →ALCAlcon Independent Director Committee Stands Firm in Commitment to Minority Shareholders o The IDC rejects Novartis' continued assertions that they can circumvent the protections afforded to the minority shareholders by S
Alcon Independent Director Committee Stands Firm in Commitment to Minority Shareholders HUENENBERG, Switzerland - September 30, 2010 - The Alcon Independent Director Committee (the "IDC") responded today to Novartis' continued assertions that they can circumvent the protections
Read more →ALCAlcon Launches TobraDex ST Suspension New product targets inflammatory eye conditions such as blepharitis
Alcon Launches TobraDex ST Suspension New product targets inflammatory eye conditions such as blepharitis HUENENBERG, Switzerland - September 22, 2010 - Alcon (NYSE: ACL), the world's leading eye care company, announced the launch of its new combination anti-inflammatory/anti-i
Read more →ALCAlcon Launches AcrySof IQ ReSTOR Toric Intraocular Lens Outside the United States
Alcon Launches AcrySof IQ ReSTOR Toric Intraocular Lens Outside the United States HUENENBERG, Switzerland - September 3, 2010 - Alcon, Inc. (NYSE: ACL), the world's leader in eye care and cataract surgery announced its launch of the AcrySof IQ ReSTOR Multifocal Toric intraocular
Read more →ALCAlcon Independent Director Committee Notes Closing of Novartis' Acquisition of Nestl 's Stake in Alcon o Closing Is an Expected Step Pursuant to Agreements Between Novartis and Nestl o Does Not Impact the IDC's Position
Alcon Independent Director Committee Notes Closing of Novartis' Acquisition of Nestl 's Stake in Alcon HUENENBERG, Switzerland - August 26, 2010 - The Alcon Independent Director Committee (the "IDC") notes the closing of Novartis AG's ("Novartis") acquisition of Nestl SA's ("Nes
Read more →ALCNovartis Completes Purchase from Nestl of Majority Interest in Alcon H U
Novartis Completes Purchase from Nestl of Majority Interest in Alcon HUENENBERG, Switzerland - August 26, 2010 - Novartis AG (NYSE: NVS) and Nestl S.A. announced today that they have completed the purchase and sale of approximately 156 million shares of Alcon, Inc. (NYSE: ACL) f
Read more →ALCAlcon Shareholders Conditionally Elect Novartis-Designated Directors H U
Shareholders Conditionally Elect Novartis-Designated Directors HUENENBERG, Switzerland - August 16, 2010 - Alcon, Inc. (NYSE:ACL) announced the following action was taken by shareholders at the extraordinary general meeting of the Alcon shareholders held today in Zug, Switzer
Read more →ALCAlcon Independent Director Committee Notes Results of Shareholder Vote Voting Minority Shareholders Overwhelmingly Reject Novartis' Designees to the Board of Alcon, Inc. at Extraordinary General Meeting IDC Says Sharehol
Independent Director Committee Notes Results of Shareholder Vote HUENENBERG, Switzerland - August 16, 2010 - The Alcon Independent Director Committee (the "IDC") notes the conditional election of five designees to the Board of Directors of Alcon, Inc. ("Alcon") proposed by No
Read more →ALCAlcon Independent Director Committee Notes RiskMetrics Group's and Glass Lewis' Opposition to Election of Novartis' Designees to Alcon's Board of Directors o RiskMetrics and Glass Lewis Recommend Shareholders Vote Agains
Alcon Independent Director Committee Notes RiskMetrics Group's and Glass Lewis' Opposition to Election of Novartis' Designees to Alcon's Board of Directors HUENENBERG, Switzerland - August 2, 2010 - The Alcon Independent Director Committee (the "IDC") today announced that RiskM
Read more →ALCOF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES
AND EXCHANGE COMMISSION OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 File Number 001-31269 of registrant's name into English) H nenberg, Switzerland of principal executive offices) by check mark whether the registran
Read more →ALCAlcon Independent Director Committee Commends Alcon on Stronger Than Expected Q2 Earnings o Alcon Exceeds Street Estimates 29 out of 32 Quarters Since its IPO o Alcon Management and Employees Continue to Build Shareholde
Independent Director Committee Commends Alcon on Stronger Than Expected Q2 HUENENBERG, Switzerland - July 26, 2010 - The Alcon Independent Director Committee (the "Committee") noted today that Alcon once again delivered strong earnings in the second quarter of 2010. Alcon's 2
Read more →ALCInvitation to an Extraordinary General Meeting of Alcon, Inc. __________________________ Monday
General Meeting of Alcon, Inc. __________________________ August 16, 2010, 10:00 a.m. (doors open at 9:00 a.m.) Center Metalli at the Parkhotel Zug, CH-6304 Zug, Switzerland elections to the Board of Directors (Conditional Resolution) On behalf of our Board of Directors, we
Read more →ALCAlcon Independent Director Committee Announces Meeting with Minority Shareholders H U
Independent Director Committee Announces Meeting with Minority HUENENBERG, Switzerland - July 14, 2010 - The Alcon Independent Director Committee (the "IDC") announced that it is holding a meeting for Alcon's minority shareholders at 8:00 AM EDT today, July 14, 2010, at the G
Read more →ALCAlcon Independent Director Committee Announces Creation and Funding of Litigation Trust o Alcon Litigation Trust created to protect minority shareholders against attempts to circumvent fair process once Novartis' acquisi
Independent Director Committee Announces Creation and Funding of Litigation HUENENBERG, Switzerland - July 8, 2010 - The Alcon Independent Director Committee (the "IDC") announced today the creation and funding of the Alcon Litigation Trust (the "Trust"), an irrevocable trust
Read more →ALCAlcon to Acquire LenSx Lasers, Inc., Developer of Femtosecond Laser Technology for Increased Precision of Manual Surgical Steps during Cataract Surgery
to Acquire LenSx Lasers, Inc., Developer of Femtosecond Laser Technology for Increased Precision of Manual Surgical Steps during Cataract HUENENBERG, Switzerland - July 6, 2010 - Alcon, Inc. (NYSE: ACL) announced today that it has entered into a definitive agreement to acquir
Read more →ALCAlcon Announces Shareholder Meeting to Effect Previously Agreed Conditional Replacement of Nestl -Nominated Directors H U
Alcon Announces Shareholder Meeting to Effect Previously Agreed Conditional Replacement of Nestl -Nominated Directors HUENENBERG, Switzerland - June 30, 2010 - Alcon, Inc. (NYSE:ACL) ("Alcon") announced today that the Alcon board of directors resolved to hold an extraordinary ge
Read more →ALCAlcon Independent Director Committee Responds to Notice of Alcon EGM to Put Forth Novartis-Designated Director Candidates o The announced shareholder meeting is a necessary and expected step required by the 2008 agreemen
Alcon Independent Director Committee Responds to Notice of Alcon EGM to Put Forth Novartis-Designated Director Candidates HUENENBERG, Switzerland - June 30, 2010 - The Alcon Independent Director Committee (the "IDC") notes that the recently announced extraordinary general meetin
Read more →ALCSwiss Corporate Governance Expert Supports Alcon Independent Director Committee's Position against Novartis o Leading Swiss Corporate Governance Expert Says Novartis' Merger Proposal Cannot Be Approved by the Alcon Board
Corporate Governance Expert Supports Alcon Independent Director Committee's Position against Novartis HUENENBERG, Switzerland - June 28, 2010 - The Alcon Independent Director Committee (the "IDC") announced today that Professor Hans Caspar von der Crone, a leading Swiss legal
Read more →ALCAlcon Shareholders Approve Dividend, Elect Directors
Shareholders Approve Dividend, Elect Directors HUENENBERG, Switzerland - May 20, 2010 - Alcon, Inc. (NYSE:ACL) announced the following actions were taken by shareholders at the company's Annual General Meeting of Shareholders held today in Zug, Switzerland: company also anno
Read more →ALCStatuten der Alcon, Inc. vom 20. Mai 2010 Articles of Association of Alcon, Inc. as of
Articles of Association of Abschnitt 1: Firma, Sitz, Zweck und Dauer der Gesellschaft Section 1: Name, Place of Incorporation, Purpose and Duration Firma, Sitz Artikel 1 Unter der Firma Alcon, Inc. besteht eine Aktiengesellschaft mit Sitz in H nenberg ZG. Name, Place of Inc
Read more →ALCAlcon Independent Director Committee Notes that Novartis' Grossly Inadequate Merger Proposal Continues to Deteriorate Even in the Face of Alcon's Strong Earnings o Alcon's Strong Q1 Earnings Demonstrate Superior Growth O
Independent Director Committee Notes that Novartis' Grossly Inadequate Merger Proposal Continues to Deteriorate Even in the Face of Alcon's Strong HUENENBERG, Switzerland - April 27, 2010 - The Alcon Independent Director Committee (the "Committee") reiterated today that the N
Read more →ALCSECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2010 Commission File Number 001-31269 (Translation of registrant's name into English)
Read more →ALCInvitation to the Annual General Meeting of Alcon, Inc. __________________________ Thursday
General Meeting of Alcon, Inc. __________________________ May 20, 2010, 2:00 p.m. (doors open at 1:00 p.m.) Center Metalli at the Parkhotel Zug, CH-6304 Zug, Switzerland On behalf of our Board of Directors, we would like to invite you to the Annual General Meeting of Shareho
Read more →ALCALCON, INC. B sch 69 P.O. Box 62 H nenberg, Switzerland 2009 FINANCIAL REPORT 2 ALCON, INC. 2009 FINANCIAL REPORT TABLE OF CONTENTS Page Reference Management's Report on Internal Control over Financial Reporting 5 Report
Page Reference Management's Report on Internal Control over Financial Reporting 5 Reports of Independent Registered Public Accounting Firm 6 Consolidated Balance Sheets 8 Consolidated Statements of Earnings 9 Consolidated Statements of Shareholders' Equity and Comprehensi
Read more →ALCAlcon Completes Acquisition of Durezol and Zyclorin from Sirion
Completes Acquisition of Durezol and Zyclorin from Sirion HUENENBERG, Switzerland - March 29, 2010 - Alcon (NYSE: ACL), the world's leader in eye care, announced today that it received regulatory approval and finalized the acquisition of the rights in the United States for DU
Read more →ALCExhbit 99.1 EXECUTION COPY Alcon, Inc. P.O. Box 62 B sch 69CH-6331 H nenberg Switzerland
We refer you to the Amended and Restated Registration Rights Agreement, dated as of December 10, 2009 (the Rights Agreement"), between Alcon, Inc., a company organized under the laws of Switzerland (the "Company") and Nestl S.A., a company organized under the laws of Switzerl
Read more →ALCGroup Questions Adequacy and Legality of Novartis' Merger Proposal to Alcon's
Group Questions Adequacy and Legality of Novartis' Merger Proposal to Alcon's Minority Shareholders HUENENBERG, Switzerland - February 17, 2010 - The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. (NYSE: ACL) today announced that RiskMetrics Group, Inc
Read more →ALCAlcon Independent Director Committee Says Company's Q4/FY 2009 Financial Results Underscore Gross Inadequacy of Novartis' Proposal to Minority Shareholders o The Committee Applauds Alcon Management and Employees for Outs
Independent Director Committee Says Company's Q4/FY 2009 Financial Results Underscore Gross Inadequacy of Novartis' Proposal to Minority HUENENBERG, Switzerland - February 12, 2009 - The Alcon (NYSE: ACL) Independent Director Committee today said that Alcon's impressive Q4/FY
Read more →ALCAlcon Independent Director Committee Determines Novartis' Merger Proposal to Minority Shareholders of Alcon is Grossly Inadequate o Alcon's Standalone Value Dramatically Exceeds Novartis' Proposal o Novartis' Financial A
Independent Director Committee Determines Novartis' Merger Proposal to Minority Shareholders of Alcon is Grossly Inadequate HUENENBERG, Switzerland - January 20, 2010 - The Independent Director Committee (the "Committee") of Alcon, Inc. (NYSE: announced that it formally respo
Read more →ALCAlcon to Purchase Ophthalmic Pharmaceutical Assets from Sirion
to Purchase Ophthalmic Pharmaceutical Assets from Sirion HUENENBERG, Switzerland - January 18, 2010 - Alcon (NYSE: ACL), the world's leader in eye care, announced today that it will purchase the rights in the United States for two FDA-approved topical eye care products from Si
Read more →ALCAlcon Independent Director Committee Reviewing Novartis' Merger Proposal
Independent Director Committee Reviewing Novartis' Merger Proposal HUENENBERG, Switzerland - January 4, 2010 - Alcon, Inc. (NYSE: ACL) announced that Novartis AG (NYSE: NVS) has exercised its option to purchase the remaining shares in Alcon owned by Nestle S.A. at a weighted
Read more →ALCNovartis Announces Option Exercise and Merger Proposal
Announces Option Exercise and Merger Proposal HUENENBERG, Switzerland - January 4, 2010 - Novartis AG (NYSE: NVS) announced today that it had exercised its option to purchase the remaining shares in Alcon, Inc. (NYSE: ACL) owned by Nestle S.A. at a weighted average price of U
Read more →ALCINDEPENDENT DIRECTOR COMMITTEE RESPONDS TO NOVARTIS
INDEPENDENT DIRECTOR COMMITTEE RESPONDS TO NOVARTIS HUENENBERG, Switzerland - January 04, 2010 - The Alcon, Inc. (NYSE: ACL) Independent Director Committee, in response to comments made today by Novartis AG (NYSE: NVS), stated its belief that Alcon has established certain imp
Read more →ALCAlcon to Enter Surgical Glaucoma Market by Acquiring Optonol Acquisition reflects increasing importance of glaucoma surgery to preserve vision Entry into glaucoma surgery provides additional near term growth opportunity
to Enter Surgical Glaucoma Market by Acquiring Optonol HUENENBERG, Switzerland - December 14, 2009 - Alcon (NYSE: ACL) announced today that it has entered into a definitive agreement to acquire Optonol, Ltd., a medical device company that develops, manufactures and markets no
Read more →ALCAlcon to Acquire Swiss Biotechnology Firm, ESBATech AG Company gains access to proprietary antibody fragment technology particularly suited to treat eye diseases Acquisition establishes sustainable
Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG HUENENBERG and ZURICH, Switzerland - September 14, 2009 - Alcon (NYSE: ACL) announced today that it has entered into a definitive agreement to acquire ESBATech AG, a Swiss biotechnology company. Alcon will pay ESBATech shar
Read more →ALCAlcon and AstraZeneca to Collaborate on Eye Drug Development
Alcon and AstraZeneca to Collaborate on Eye Drug Development HUENENBERG, Switzerland - July 22, 2009 - Alcon (NYSE: ACL) announced today that it has entered into a five-year collaborative research agreement with AstraZeneca for the exclusive ophthalmic discovery and potential de
Read more →ALCAlcon Breaks Ground in Singapore on First Asian Pharmaceutical Manufacturing Plant Ceremony Held Today for New Facility in Tuas Biomedical Park
Breaks Ground in Singapore on First Asian Pharmaceutical Manufacturing Held Today for New Facility in Tuas Biomedical Park HUENENBERG, Switzerland - May 26, 2009 - Alcon (NYSE: ACL), the world's largest manufacturer of eye care products, marked the commencement of constructio
Read more →ALCAlcon Achieves Required Ownership in WaveLight AG to Initiate Squeeze-out
Achieves Required Ownership in WaveLight AG to Initiate Squeeze-out HUENENBERG, Switzerland - May 12, 2009 - Alcon, Inc., (NYSE: ACL) announced today that the company has achieved ownership of more than 95 percent of the share capital of WaveLight AG (ISIN: DE0005125603). Und
Read more →ALCAlcon Shareholders Approve Dividend Increase and Elect New Members to the Board
Shareholders Approve Dividend Increase and Elect New Members to the HUENENBERG, Switzerland - May 5, 2009 - Alcon, Inc., (NYSE: ACL) announced the following actions were taken by shareholders at the company's Annual General Meeting of Shareholders held today in Zug, company
Read more →ALCALCON, INC. B sch 69 P.O. Box 62 H nenberg, Switzerland 2008 FINANCIAL REPORT 2 ALCON, INC. 2008 FINANCIAL REPORT TABLE OF CONTENTS Page Reference Management's Report on Internal Control over Financial Reporting 5 Report
Page Reference Management's Report on Internal Control over Financial Reporting 5 Reports of Independent Registered Public Accounting Firm 6 Consolidated Balance Sheets 8 Consolidated Statements of Earnings 9 Consolidated Statements of Shareholders' Equity and Comprehensi
Read more →ALCInvitation to the Annual General Meeting of Alcon, Inc. __________________________ Tuesday
General Meeting of Alcon, Inc. __________________________ May 5, 2009, 2:00 p.m. (doors open at 1:00 p.m.) Center Metalli at the Parkhotel Zug, CH-6304 Zug, Switzerland On behalf of our Board of Directors, we would like to invite you to the Annual General Meeting of Sharehol
Read more →ALCAlcon Signs Contract with LCA-Vision for 75 ALLEGRETTO WAVE Excimer Lasers LASIK chain standardizes with high-end technology based on study results.
Signs Contract with LCA-Vision for 75 ALLEGRETTO WAVE chain standardizes with high-end technology based on study results. HUENENBERG, Switzerland - March 10, 2009 - Alcon, Inc. (NYSE: ACL) announced today that its affiliate Alcon Laboratories, Inc. has signed a five year cont
Read more →ALCALCON EXECUTIVE DEFERRED COMPENSATION PLAN EFFECTIVE DATE
EXECUTIVE DEFERRED COMPENSATION PLAN EFFECTIVE DATE: January 1, EXECUTIVE DEFERRED COMPENSATION PLAN V. Administration of the VII. Plan Accounts 13 IX. Change in Distribution X. Offset for Obligations to XIV. Determination of XVII. Unfunded Status of Section 409A Complia
Read more →ALCStatuten der Alcon, Inc. vom 13. Februar 2009 Articles of Association of Alcon, Inc. as of
vom 13. Februar 2009 Articles of Association as of February 13, 2009 Abschnitt 1: Firma, Sitz, Zweck und Dauer der Gesellschaft Section 1: Name, Place of Incorporation, Purpose and Duration Firma, Sitz Artikel 1 Unter der Firma Alcon, Inc. besteht eine Aktiengesellschaft
Read more →ALCALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS February 2009 ALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS Table of Contents ARTICLE I Authority 3 ARTICLE II Executive Bodies of the Company 3 ARTIC
II Executive Bodies of the Company 3 IV Chairman and the Vice-Chairman 8 VI Executive Officers of the Company and the Group 15 VII Chief Executive Officer 16 VIII Conflict of Interest 16 IX Interests in Shares and Options 19 General Provisions 20 XI Final Provisions 20 Th
Read more →ALCKevin Buehler Appointed President and CEO of Alcon; Cary Rayment to Continue as Chairman of the Board H
Buehler Appointed President and CEO of Alcon; Cary Rayment to Continue as Chairman of the Board H NENBERG, Switzerland - January 8, 2009 - Alcon, Inc. (NYSE:ACL) announced today that on April 1, 2009 Kevin Buehler will become president and chief executive officer of Alcon, I
Read more →ALCFDA Approves Alcon's AcrySof IQ ReSTOR + 3.0 D Intraocular Lens New lens corrects for cataracts with presbyopia
FDA Approves Alcon's + 3.0 D Intraocular Lens lens corrects for cataracts with presbyopia HUENENBERG, Switzerland - December 23, 2008 - Alcon, Inc. (NYSE: ACL), the world's leader in eye care and cataract surgery announced that the U.S. Food and Drug Administration (FDA) app
Read more →ALCAZARGA Ophthalmic Suspension Approved for Treatment of Patients with Glaucoma or Ocular Hypertension in the European Union Huenenberg, Switzerland
Ophthalmic Suspension Approved for Treatment of Patients with Glaucoma or Ocular Hypertension in the European Union Huenenberg, Switzerland - December 2, 2008 - Alcon, Inc. (NYSE:ACL) announced today that the European Medicines Agency (EMEA) has approved Alcon's fixed combina
Read more →ALCAlcon, Inc. Slides used during the Alcon, Inc. AAO Presentation
Alcon, Inc. Slides used during the Alcon, Inc. AAO Presentation November 7, 2008
Read more →ALCAlcon Announces Two Agreements Designed to Expand Its Future Drug Portfolio H
Alcon Announces Two Agreements Designed to Expand Its Future Drug Portfolio H NENBERG, Switzerland October 14, 2008 Alcon, Inc. (NYSE: ACL) announced today that it has executed a new agreement and broadened an existing agreement with two different companies to expand its product
Read more →ALCAlcon Plans to Expand Manufacturing Facility in West Virginia H
Alcon Plans to Expand Manufacturing Facility in West Virginia H NENBERG, Switzerland September 19, 2008 Alcon, Inc. (NYSE:ACL) announced today that the company plans to expand its medical device manufacturing facility in Cabell County, West Virginia. The company hosted a groundb
Read more →ALCAlcon Launches New AcrySof ReSTOR Intraocular Lens for Presbyopia Outside the
Alcon Launches New AcrySof ReSTOR Intraocular Lens for Presbyopia Outside the U.S. HUENENBERG, Switzerland September 15, 2008 Alcon, Inc. (NYSE: ACL), the world s leader in eye care and intraocular lenses (IOLs), announced the commercial launch outside the U.S. of the new +3.0 A
Read more →ALCAlcon Expands Refractive Surgery Options with the Introduction of the AcrySof Phakic Intraocular Lens Outside the
Alcon Expands Refractive Surgery Options with the Introduction of the AcrySof Phakic Intraocular Lens Outside the U.S. HUENENBERG, Switzerland September 12, 2008 Alcon, Inc. (NYSE: ACL) announced the international release of the new AcrySof Phakic Lens at the 2008 European Soci
Read more →ALCAlcon Plans to Repurchase Up to One Million Shares H
Alcon Plans to Repurchase Up to One Million Shares H NENBERG, Switzerland September 8, 2008 Alcon, Inc. (NYSE: ACL) announced today that it intends to repurchase up to one million common shares by December 31, 2008. The company will purchase the shares from the public to cover e
Read more →ALCAlcon's Second Quarter Sales Rise 17.9 Percent; Net Earnings Increase 26.3 Percent
Alcon's Second Quarter Sales Rise 17.9 Percent; Net Earnings Increase 26.3 Percent HUENENBERG, Switzerland - July 23, 2008 - Alcon, Inc. (NYSE:ACL) reported global sales of $1,735.2 million for the second quarter of 2008, an increase of 17.9 percent compared to the second qua
Read more →ALCAlcon Terminates the Development of Anecortave Acetate in Age-Related Macular Degeneration
Alcon Terminates the Development of Anecortave Acetate in Age-Related Macular Degeneration HUENENBERG, Switzerland July 11, 2008 Alcon, Inc. (NYSE:ACL) announced today it has terminated the development program designed to evaluate the benefit of anecortave acetate treatment on t
Read more →ALCNovartis Completes Purchase of Minority Interest in Alcon
Novartis Completes Purchase of Minority Interest in Alcon HUENENBERG, Switzerland July 8, 2008 Novartis AG and Nestl S.A. announced today that they have completed the first step purchase and sale of 74 million shares of Alcon, Inc. (NYSE: ACL) common stock currently owned by Nes
Read more →ALCAlcon Enters Into Patent Cross-Licensing Agreement With
Alcon Enters Into Patent Cross-Licensing Agreement With AMO HUENENBERG, Switzerland June 24, 2008 Alcon, Inc. (Alcon) [NYSE: ACL] announced today that it has entered into a patent cross-licensing agreement with Advanced Medical Optics, Inc. (AMO) [NYSE: EYE] relating to lubricio
Read more →ALCAlcon Shareholders Approve Increased Dividend and Elect New Members to the Board H
Alcon Shareholders Approve Increased Dividend and Elect New Members to the Board H NENBERG, Switzerland May 6, 2008 Alcon, Inc., (NYSE: ACL) announced the following actions were taken by shareholders at the company s Annual General Meeting of Shareholders held today in Zug, Swit
Read more →ALCAlcon s First Quarter Sales Rise 16.2 Percent; Net Income Increases 24.0 Percent
Alcon s First Quarter Sales Rise 16.2 Percent; Net Income Increases 24.0 Percent HUENENBERG, Switzerland April 23, 2008 Alcon, Inc. (NYSE:ACL) reported global sales of $1,536.4 million for the first quarter of 2008, an increase of 16.2 percent compared to the first quarter of 20
Read more →ALCAlcon s PATANASE Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
Alcon s PATANASE Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms HUENENBERG, Switzerland April 15, 2008 Alcon, Inc. (NYSE: ACL) announced today that the U.S. Food and Drug Administration (FDA) has approved PATANASE (olopatadine hydrochloride) nasal spray for
Read more →ALCAlcon Announces Plans to Build Pharmaceutical Manufacturing Plant in Singapore HUENENBERG, Switzerland April 13 Alcon, Inc. (NYSE:ACL) announced today that the company plans to build a facility in Singapore that will man
Alcon Announces Plans to Build Pharmaceutical Manufacturing Plant in Singapore HUENENBERG, Switzerland April 13 Alcon, Inc. (NYSE:ACL) announced today that the company plans to build a facility in Singapore that will manufacture pharmaceuticals to be distributed throughout most
Read more →ALCNovartis to Acquire 25 Percent Minority Stake in Alcon from Nestl
Novartis to Acquire 25 Percent Minority Stake in Alcon from Nestl HUENENBERG, Switzerland April 7, 2008 Nestl S.A. and Novartis AG announced today that they have reached an agreement pursuant to which Nestl will sell 74 million of its shares of Alcon, Inc. (NYSE:ACL) common stoc
Read more →ALCALCON, INC. B sch 69 P.O. Box 62 H nenberg, Switzerland 2007 FINANCIAL REPORT ALCON, INC. 2007 FINANCIAL REPORT TABLE OF CONTENTS Page Reference Management's Report on Internal Control over Financial Reporting 3 Reports
H nenberg, Switzerland 2007 FINANCIAL REPORT 2007 FINANCIAL REPORT Page Reference Management's Report on Internal Control over Financial Reporting 3 Reports of Independent Registered Public Accounting Firm 4 Consolidated Balance Sheets 6 Consolidated Statements of Earni
Read more →ALCAlcon Announces Leadership Change to Research and Development Organization
Alcon Announces Leadership Change to Research and Development Organization HUENENBERG, Switzerland March 10, 2008 - Alcon, Inc. (NYSE:ACL) announced today that Gerald D. Cagle, Ph.D., Alcon s senior vice president of Research and Development and chief scientific officer, will be
Read more →ALCAlcon Presents Clinical Trial Data on Anecortave Acetate for Glaucoma Washington, DC
Alcon Presents Clinical Trial Data on Anecortave Acetate for Glaucoma Washington, DC March 6, 2008 Alcon, Inc. (NYSE: ACL) released today the primary efficacy and safety results of the second controlled proof of concept clinical study of anecortave acetate administered as an ant
Read more →ALCALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS February 2008 ALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS Table of Contents ARTICLE I Authority 3 ARTICLE II Executive Bodies of the Company 3 ARTIC
ORGANIZATIONAL REGULATIONS ORGANIZATIONAL REGULATIONS Section 1. Authority. These Organizational Regulations (the Regulations) are enacted by the Board of Directors of Alcon, Inc. (the Company) pursuant to art. 716b of the Swiss Code of Obligations (CO) and art. 21 para. 1 and
Read more →ALCAlcon s Fourth Quarter Sales Rise 20.0 Percent
Alcon s Fourth Quarter Sales Rise 20.0 Percent HUNENBERG, Switzerland February 6, 2008 Alcon, Inc. (NYSE:ACL) reported global sales of $1,469.7 million for the fourth quarter of 2007, an increase of 20.0 percent over global sales for the fourth quarter of 2006, or 12.8 percent e
Read more →ALCALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS December 2007 ALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS Table of Contents ARTICLE I Authority 3 ARTICLE II Executive Bodies of the Company 3 ARTIC
ORGANIZATIONAL REGULATIONS ORGANIZATIONAL REGULATIONS Section 1. Authority. These Organizational Regulations (the Regulations) are enacted by the Board of Directors of Alcon, Inc. (the Company) pursuant to art. 716b of the Swiss Code of Obligations (CO) and art. 21 para. 1 and
Read more →ALCALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS December 2007 ALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS Table of Contents Article I Authority 3 Article II Executive Bodies of the Company 3 Artic
ORGANIZATIONAL REGULATIONS ORGANIZATIONAL REGULATIONS Article I Authority 3 Article II Executive Bodies of the Company 3 Article III The Board 4 Article IV Chairman and the Vice-Chairman 8 Article V Board Committees 9 Article VI Executive Officers of the Company and the Group 1
Read more →ALCAlcon Announces New Share Repurchase Program
Alcon Announces New Share Repurchase Program HUENENBERG, Switzerland December 5, 2007 - Alcon, Inc. (NYSE:ACL) announced today that its board of directors approved a new share repurchase program that allows for the purchase of up to $1.1 billion of shares of outstanding common s
Read more →ALCAlcon Receives FDA Approval of TRIESENCE Injectable Triamcinolone Suspension for Use in Eye Surgery
Alcon Receives FDA Approval of TRIESENCE Injectable Triamcinolone Suspension for Use in Eye HUENENBERG, Switzerland November 30, 2007 Alcon (NYSE:ACL) announced today that the United States Food and Drug Administration (FDA) has approved TRIESENCE (triamcinolone acetonide inj
Read more →ALCAlcon Gains All Regulatory Clearances for Acquisition of WaveLight
Alcon Gains All Regulatory Clearances for Acquisition of WaveLight AG HUENENBERG, Switzerland November 6, 2007 Alcon (NYSE:ACL) announced today that it now has received all required regulatory clearances related to its tender offer for WaveLight AG. With all closing conditions n
Read more →ALCAlcon s Third Quarter Sales Rise 11.0 Percent
Alcon s Third Quarter Sales Rise 11.0 Percent HUNENBERG, Switzerland October 24, 2007 Alcon, Inc. (NYSE:ACL) reported global sales of $1,335.7 million for the third quarter of 2007, an increase of 11.0 percent over global sales for the third quarter of 2006, or 7.9 percent on a
Read more →ALCPublic Takeover Period of WaveLight AG Ends
Public Takeover Period of WaveLight AG Ends HUENENBERG, Switzerland - October 18, 2007 - Alcon's public takeover offer period for WaveLight AG has ended. Settlement of the transaction will take place upon cartel clearance in China and Cyprus. Alcon received cartel clearance in S
Read more →ALCAlcon Amends NDA for Patanase Nasal Spray
Alcon Amends NDA for Patanase Nasal Spray HUENENBERG, Switzerland October 10, 2007 Alcon, Inc. (NYSE: ACL) announced today that it has submitted to the U.S. Food and Drug Administration (FDA) an amendment to its pending new drug application (NDA) for PATANASE (olopatadine hydroc
Read more →ALCAlcon Gains 76.9 Percent of WaveLight Shares and Will Move Forward with Acquisition
Alcon Gains 76.9 Percent of WaveLight Shares and Will Move Forward with Acquisition HUENENBERG, Switzerland September 28, 2007 - Alcon, Inc. (NYSE:ACL) announced today that the company has gained control of 76.9 percent of WaveLight's approximately 6.6 million issued and outstan
Read more →ALCAlcon Receives FDA Decision on RETAANE Suspension for Wet
Alcon Receives FDA Decision on RETAANE Suspension for Wet AMD HUENENBERG, Switzerland September 24, 2007 - Alcon, Inc. (NYSE:ACL) announced today that the company received an approvable letter from the United States Food and Drug Administration (FDA) for RETAANE 15 mg (anecortav
Read more →ALCAlcon s Stake in WaveLight AG at 73.5 Percent
Alcon s Stake in WaveLight AG at 73.5 Percent HUENENBERG, Switzerland September 21, 2007 - Alcon, Inc. (NYSE:ACL) announced today that the company now holds 73.5 percent of WaveLight AG outstanding shares through tender, contractual commitment or purchase. Additionally, the comp
Read more →ALCAlcon Exceeds 70 Percent Stake in WaveLight
Alcon Exceeds 70 Percent Stake in WaveLight AG HUENENBERG, Switzerland September 17, 2007 - Alcon, Inc. (NYSE:ACL) announced today that the company now holds over 70 percent of WaveLight AG outstanding shares through purchase, contractual commitment or tender. Additionally, Alco
Read more →ALCAlcon Waives Minimum Acceptance Condition for WaveLight
Alcon Waives Minimum Acceptance Condition for WaveLight AG HUENENBERG, Switzerland September 10, 2007 - Alcon, Inc. (NYSE:ACL) announced today that it has amended its tender offer for Wavelight AG and waived the minimum tender offer acceptance threshold of 75 percent of all Wave
Read more →ALCAlcon Announces Expansion of Swiss Operations
Alcon Announces Expansion of Swiss Operations HUENENBERG, Switzerland September 10, 2007 - Alcon, Inc. (NYSE:ACL) announced today that it expects to establish Fribourg, Switzerland as the central location for an expansion of the company s Swiss-managed global administration oper
Read more →ALCALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS September 2007 ALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS Table of Contents ARTICLE I Authority 3 ARTICLE II Executive Bodies of the Company 3 ARTI
ORGANIZATIONAL REGULATIONS ORGANIZATIONAL REGULATIONS Section 1. Authority. These Organizational Regulations (the Regulations) are enacted by the Board of Directors of Alcon, Inc. (the Company) pursuant to art. 716b of the Swiss Code of Obligations (CO) and art. 21 para. 1 and
Read more →ALCAlcon Confirms That Carl Zeiss Meditec AG Will Tender All WaveLight AG Shares
HUENENBERG, Switzerland September 7, 2007- Alcon, Inc. (NYSE:ACL) confirmed today that Carl Zeiss Meditec AG, which owns approximately a five percent stake in WaveLight AG, issued a press release earlier today indicating Zeiss will tender all of its WaveLight shares to Alcon at t
Read more →ALCAlcon s Tender Offer Endorsed by WaveLight AG s Executive Committee and Supervisory Board
Alcon s Tender Offer Endorsed by WaveLight AG s Executive Committee and Supervisory Board HUENENBERG, Switzerland August 20, 2007 - Alcon, Inc. (NYSE:ACL) announced today that the company received a joint recommendation issued by WaveLight AG s Executive Committee and Supervisor
Read more →ALCAlcon s Tender Offer for WaveLight AG Approved by German Federal Financial Supervisory Authority
Alcon s Tender Offer for WaveLight AG Approved by German Federal Financial Supervisory Authority HUENENBERG, Switzerland August 10, 2007 Alcon, Inc. (NYSE:ACL) announced today that the German Federal Financial Supervisory Authority (BaFin) has approved publication of the company
Read more →ALCAlcon s Treatment of Glaucoma and Ocular Hypertension, TRAVATANZ Solution, Approved in Japan
Alcon s Treatment of Glaucoma and Ocular Hypertension, TRAVATANZ Solution, Approved in Japan FORT WORTH, Texas July 31, 2006 Alcon, Inc. (NYSE: ACL) announced today that the Ministry of Health, Labor and Welfare in Japan has approved TRAVATANZ (travoprost ophthalmic solution) 0.
Read more →ALCAlcon s Second Quarter Sales Rise 12.3 Percent
Alcon s Second Quarter Sales Rise 12.3 Percent HUNENBERG, Switzerland July 25, 2007 Alcon, Inc. (NYSE:ACL) reported global sales of $1,471.5 million for the second quarter of 2007, an increase of 12.3 percent over global sales for the second quarter of 2006, or 10.0 percent on a
Read more →ALCAnecortave Acetate Clinical Trial Data for Glaucoma Presented at World Congress of Glaucoma Singapore
Anecortave Acetate Clinical Trial Data for Glaucoma Presented at World Congress of Glaucoma Singapore July 17, 2007 Alcon, Inc. (NYSE: ACL) released today the three-month interim results of the first controlled clinical study of anecortave acetate administered as an anterior ju
Read more →ALCRichard Croarkin Appointed CFO of Alcon
Richard Croarkin Appointed CFO of Alcon HUENENBERG, Switzerland - July 16, 2007 - Alcon, Inc. (NYSE:ACL) announced today that effective August 1, Richard Croarkin will be named senior vice president and chief financial officer. Croarkin comes to Alcon from Nestle, SA, where he w
Read more →ALCAlcon Announces Offer for WaveLight
Alcon Announces Offer for WaveLight AG HUENENBERG, Switzerland July 16, 2007 - Alcon, Inc. (NYSE:ACL) announced today that the company intends to acquire WaveLight AG (ISIN DE: 000 512 5603) through a friendly takeover and that the parties have entered into a business combinatio
Read more →ALCJacqualyn Fouse to Leave Alcon for New Position
Jacqualyn Fouse to Leave Alcon for New Position HUENENBERG, Switzerland - June 26, 2007 - Alcon, Inc. (NYSE:ACL) announced today that effective July 20, 2007, Jacqualyn Fouse, Alcon s senior vice president, chief financial officer and corporate strategy will leave the company to
Read more →ALCALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS May 2007 ALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS Table of Contents Article I Authority 3 Article II Executive Bodies of the Company 3 Article II
ORGANIZATIONAL REGULATIONS ORGANIZATIONAL REGULATIONS Article I Authority 3 Article II Executive Bodies of the Company 3 Article III The Board 4 Article IV Chairman and the Vice-Chairman 8 Article V Board Committees 9 Article VI Executive Officers of the Company and the Group 1
Read more →ALCAlcon Shareholders Approve Dividend and Elect a New Member to the Board H
Alcon Shareholders Approve Dividend and Elect a New Member to the Board H NENBERG, Switzerland - May 9, 2007 - Alcon, Inc., (NYSE: ACL) announced the following actions were taken by shareholders at the company s Annual General Meeting of Shareholders held today in Zug, Switzerla
Read more →ALCAlcon s First Quarter Sales Rise 14.3 Percent
Alcon s First Quarter Sales Rise 14.3 Percent HUNENBERG, Switzerland April 25, 2007 Alcon, Inc. (NYSE:ACL) reported global sales of $1,322.7 million for the first quarter of 2007, an increase of 14.3 percent compared to the first quarter of 2006, or 12.0 percent excluding the im
Read more →ALCAlcon Invitation to the Annual General Meeting of Alcon, Inc. __________________________ Wednesday
Annual General Meeting of Alcon, Inc. __________________________ Wednesday, May 9, 2007, 2:00 p.m. (doors open at 1:00 p.m.) Congress Center Metalli at the Parkhotel Zug, CH-6304 Zug, Switzerland 2006 Consolidated Financial Statements of Alcon, Inc. and Subsidiaries for the
Read more →ALCALCON, INC. B sch 69 P.O. Box 62 H nenberg, Switzerland 2006 FINANCIAL REPORT ALCON, INC. 2006 FINANCIAL REPORT TABLE OF CONTENTS Page Reference Management's Report on Internal Control over Financial 3 Reporting Reports
H nenberg, Switzerland 2006 FINANCIAL REPORT 2006 FINANCIAL REPORT Page Reference Management's Report on Internal Control over Financial 3 Reporting Reports of Independent Registered Public Accounting Firm 4 Consolidated Balance Sheets 6 Consolidated Statements of E
Read more →ALCAlcon s Fourth Quarter Sales Rise 16.1 Percent
Alcon s Fourth Quarter Sales Rise 16.1 Percent HUNENBERG, Switzerland February 7, 2007 Alcon, Inc. (NYSE:ACL) reported global sales of $1,224.9 million for the fourth quarter of 2006, an increase of 16.1 percent over global sales for the fourth quarter of 2005, or 13.5 percent e
Read more →ALCAlcon s AcrySof ReSTOR Apodized Diffractive Aspheric Intraocular Lens Approved by
Alcon s AcrySof ReSTOR Apodized Diffractive Aspheric Intraocular Lens Approved by FDA FORT WORTH, Texas February 1, 2007 Alcon Laboratories, Inc., a subsidiary of Alcon, Inc. (NYSE: ACL), announced today that the U.S. Food and Drug Administration (FDA) has granted approval of th
Read more →ALCCMS Ruling Provides Medicare Beneficiaries Access to Astigmatism-Correcting Intraocular Lenses
CMS Ruling Provides Medicare Beneficiaries Access to Astigmatism-Correcting Intraocular Lenses FORT WORTH, Texas January 22, 2007 Alcon Laboratories, Inc., a subsidiary of Alcon, Inc. (NYSE:ACL), announced today that the Centers for Medicare and Medicaid Services (CMS) issued a
Read more →ALCAlcon s Third Quarter Sales Rise 12.4 Percent
Alcon s Third Quarter Sales Rise 12.4 Percent HUNENBERG, Switzerland October 23, 2006 Alcon, Inc. (NYSE:ACL) reported global sales of $1,203.8 million for the third quarter of 2006, an increase of 12.4 percent over global sales in the third quarter of 2005, or 11.3 percent exclu
Read more →ALCAlcon s TRAVATAN Z Solution Approved by FDA for Treatment of Glaucoma and Ocular Hypertensive Patients
Alcon s TRAVATAN Z Solution Approved by FDA for Treatment of Glaucoma and Ocular Hypertensive Patients FORT WORTH, Texas September 21, 2006 Alcon, Inc. (NYSE: ACL) announced today that the U.S. Food and Drug Administration (FDA) has approved TRAVATAN Z (travoprost ophthalmic sol
Read more →ALCAlcon Licenses Novel Anti-Infective Compounds for Eye, Ear and Sinus Infections from NovaCal
Alcon Licenses Novel Anti-Infective Compounds for Eye, Ear and Sinus Infections from NovaCal FORT WORTH, Texas September 18, 2006 Alcon, Inc. (NYSE: ACL) announced today that one of its affiliates has signed a collaboration and license agreement with NovaCal Pharmaceuticals, Inc
Read more →ALCAlcon, Inc. Slides used during the Alcon, Inc. Presentation
Alcon, Inc. Slides used during the Alcon, Inc. Presentation September 11, 2006
Read more →ALCORGANIZATIONAL REGULATIONS
ORGANIZATIONAL REGULATIONS ORGANIZATIONAL REGULATIONS ARTICLE I Authority 3 ARTICLE II Executive Bodies of the Company 3 ARTICLE III The Board 4 ARTICLE IV Chairman and the Vice-Chairman 8 ARTICLE V Board Committees 9 ARTICLE VI Executive Officers of the Company and the Group 1
Read more →ALCAlcon Increases Share Repurchase Program
Alcon Increases Share Repurchase Program HUNENBERG, Switzerland September 8, 2006 Alcon, Inc. (NYSE:ACL) announced today that its Board of Directors has approved the repurchase of up to an additional 5.0 million shares of the company s outstanding common stock. Including this an
Read more →ALCAlcon s Eye Allergy Drug, PATANOL Ophthalmic Solution, Approved in Japan
Alcon s Eye Allergy Drug, PATANOL Ophthalmic Solution, Approved in Japan FORT WORTH, Texas July 26, 2006 Alcon, Inc. (ACL) announced today that it has received approval from the Ministry of Health, Labor and Welfare in Japan to market its eye allergy drug, PATANOL (olopatadine h
Read more →ALCAlcon s Second Quarter Sales Rise 11.8 Percent
Alcon s Second Quarter Sales Rise 11.8 Percent HUNENBERG, Switzerland July 24, 2006 Alcon, Inc. (NYSE:ACL) reported global sales of $1,310.8 million for the second quarter of 2006, an increase of 11.8 percent over global sales in the second quarter of 2005. The fluctuations in f
Read more →ALCFor Release: Immediately Refer to: (317) 276-5795 Terra Fox (Lilly) (817) 551-8974 Doug MacHatton (Alcon) Lilly and Alcon Sign Marketing Collaboration for Potentially the First Oral Medication for Diabetic Retinopathy Ag
Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 For Release: Immediately Refer to: (317) 276-5795 Terra Fox (Lilly) (817) 551-8974 Doug MacHatton (Alcon) Lilly and Alcon Sign Marketing Collaboration for Potentially the First Oral Medication for Dia
Read more →ALCAlcon and Advanced Medical Optics Settle All Pending Patent Litigation
Alcon and Advanced Medical Optics Settle All Pending Patent Litigation FORT WORTH, Texas July 10, 2006 Alcon, Inc. (NYSE: ACL) today announced it has reached a global settlement agreement with Advanced Medical Optics (AMO) resolving all current patent disputes between the compan
Read more →ALCAcrySof IQ IOL Designated as a New Technology Intraocular Lens
AcrySof IQ IOL Designated as a New Technology Intraocular Lens FORT WORTH, Texas May 21, 2006 Alcon, Inc. (NYSE:ACL) announced today that the Centers for Medicare and Medicaid Services (CMS) recognized the AcrySof IQ intraocular lens (IOL) as belonging to the New Technology Intr
Read more →ALCAlcon Gains FDA Approval for LADAR6000 Excimer Laser and Wavefront-Guided Hyperopia
Alcon Gains FDA Approval for LADAR6000 Excimer Laser and Wavefront-Guided Hyperopia FORT WORTH, TX May 8, 2006 Alcon, Inc. (NYSE:ACL) announced today that the U.S. Food & Drug Administration (FDA) has approved its LADAR6000 Excimer Laser with high speed ablation for use in LASIK
Read more →ALCAlcon Shareholders Approve Dividend and Elect Two New Members to the Board H
Alcon Shareholders Approve Dividend and Elect Two New Members to the Board H NENBERG, Switzerland May 2, 2006 Alcon, Inc., (NYSE: ACL) announced the following actions were taken by shareholders at the company s Annual General Meeting of Shareholders held today in Zug, Switzerlan
Read more →ALCAlcon and Amgen Sign Collaboration Agreement to Develop and Commercialize Innovative Therapies in Ophthalmology FORT WORTH, Texas and THOUSAND OAKS, California (APRIL 24, 2006) Alcon, Inc. (NYSE: ACL), the world s leadin
Alcon and Amgen Sign Collaboration Agreement to Develop and Commercialize Innovative Therapies in Ophthalmology FORT WORTH, Texas and THOUSAND OAKS, California (APRIL 24, 2006) Alcon, Inc. (NYSE: ACL), the world s leading eye care company and Amgen (NASDAQ: AMGN), the world s la
Read more →ALCAlcon s First Quarter Sales Rise 8.1 Percent, Net Earnings Increase 18.5 Percent
Alcon s First Quarter Sales Rise 8.1 Percent, Net Earnings Increase 18.5 Percent HUNENBERG, Switzerland April 24, 2006 Alcon, Inc. (NYSE:ACL) reported global sales of $1,157.1 million for the first quarter of 2006, an increase of 8.1 percent over global sales in the first quarte
Read more →ALCAlcon Files Patent Infringement Suit Against Teva Pharmaceuticals
Alcon Files Patent Infringement Suit Against Teva Pharmaceuticals FORT WORTH, Texas April 5, 2006 Alcon, Inc. (NYSE: ACL) today announced it has filed a U.S. patent infringement complaint in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals USA, I
Read more →ALCAlcon and Allergan Reach Agreement on Brimonidine 0.15% Patent Litigation
Alcon and Allergan Reach Agreement on Brimonidine 0.15% Patent Litigation FORT WORTH, Texas March 9, 2006 Alcon, Inc. (ACL) announced today that it had reached agreement to settle two patent lawsuits initiated by Allergan, Inc. Under the terms of the agreement, Allergan will dis
Read more →ALCAlcon Withdraws European Application for RETAANE Suspension
Alcon Withdraws European Application for RETAANE Suspension FORT WORTH, Texas March 3, 2006 Alcon, Inc. (NYSE:ACL) announced the withdrawal of its European marketing authorization application (MAA) for RETAANE 30mg/ml (anecortave acetate suspension for depot injection) from The
Read more →ALCAlcon Receives Positive Opinion for DuoTrav Eye Drops Solution from
Alcon Receives Positive Opinion for DuoTrav Eye Drops Solution from CHMP FORT WORTH, Texas February 24, 2006 Alcon, Inc. (NYSE:ACL) announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the initial marketing authorization for
Read more →ALCAlcon s Fourth Quarter Sales Rise 10.7 Percent
Alcon s Fourth Quarter Sales Rise 10.7 Percent HUNENBERG, Switzerland February 8, 2006 Alcon, Inc. (NYSE:ACL) reported global sales of $1,054.9 million for the fourth quarter of 2005, an increase of 10.7 percent over global sales in the fourth quarter of 2004, or 13.0 percent ex
Read more →ALCAlcon Will Appeal Ruling in Patent Case
Alcon Will Appeal Ruling in Patent Case FORT WORTH, Texas December 16, 2005 - Alcon, Inc. (NYSE:ACL) announced today that it would appeal a patent infringement ruling in favor of Advanced Medical Optics, Inc. (AMO) handed down today by a federal judge in Delaware. In the case, w
Read more →ALCAlcon s UK Operations Resume after Oil Depot Explosion
Alcon s UK Operations Resume after Oil Depot Explosion HUNENBERG, Switzerland December 15, 2005 Alcon, Inc. (NYSE:ACL) has resumed commercial operations in the United Kingdom following the temporary closure of its office and warehouse due to the fires and explosions at the Bunce
Read more →ALCAlcon Receives Approval of RETAANE Suspension in Australia
Alcon Receives Approval of RETAANE Suspension in Australia HUNENBERG, Switzerland December 12, 2005 Alcon, Inc. (NYSE:ACL) announced today that the Australian Therapeutic Goods Administration (TGA) has approved RETAANE suspension (15mg anecortave acetate suspension) for the trea
Read more →ALCAlcon Announces Wolfgang Reichenberger to Leave Board
Alcon Announces Wolfgang Reichenberger to Leave Board HUNENBERG, Switzerland - December 6, 2005 - Alcon, Inc. (NYSE:ACL) announced today that Wolfgang Reichenberger advised the board of directors that he will be stepping down from his position as a director of Alcon, effective D
Read more →ALCAlcon Presents New Clinical Data and Provides Regulatory Update on PATANASE Nasal Spray
Alcon Presents New Clinical Data and Provides Regulatory Update on PATANASE Nasal Spray ANAHEIM, California - November 7, 2005 An onset of action study shows faster allergy symptom relief with Alcon s (NYSE: ACL) olopatadine hydrochloride nasal spray 665 mcg (proposed brand name
Read more →ALCAlcon s Third Quarter Earnings Rise 52.2 Percent on 11.8 Percent Sales Growth
Alcon s Third Quarter Earnings Rise 52.2 Percent on 11.8 Percent Sales Growth HUNENBERG, Switzerland October 19, 2005 Alcon, Inc. (NYSE:ACL) reported global sales of $1,071.1 million for the third quarter of 2005, an increase of 11.8 percent over global sales in the third quart
Read more →ALCSafety of Alcon s RETAANE Suspension Confirmed at 24 Months Data Supports Clinical Equivalence to VISUDYNE *
Safety of Alcon s RETAANE Suspension Confirmed at 24 Months Data Supports Clinical Equivalence to VISUDYNE* FORT WORTH, Texas, October 13, 2005 Alcon, Inc. (NYSE:ACL) reported 24 month data from its comparative study of RETAANE 15 mg (anecortave acetate suspension) versus VISUD
Read more →ALCFDA Approves Alcon s OPTI-FREE RepleniSH
FDA Approves Alcon s OPTI-FREE RepleniSH MPDS FORT WORTH, Texas October 12, 2005 Alcon, Inc. (NYSE: ACL), announced today that the U.S. Food and Drug Administration (FDA) has cleared OPTI-FREE RepleniSH Multipurpose Disinfecting Solution (MPDS) for all soft contact lenses includ
Read more →ALCFDA Approves Alcon s AcrySof Toric Intraocular Lens
FDA Approves Alcon s AcrySof Toric Intraocular Lens FORT WORTH, Texas September 20, 2005 - Alcon, Inc., (NYSE: ACL) announced today that the U.S. Food and Drug Administration (FDA) approved the AcrySof Toric intraocular lens (IOL) for use in cataract patients with pre-existing c
Read more →ALCALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS September 2005 ALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS Table of Contents ARTICLE I Authority 3 ARTICLE II Executive Bodies of the Company 3 ARTI
ORGANIZATIONAL REGULATIONS ORGANIZATIONAL REGULATIONS ARTICLE I Authority 3 ARTICLE II Executive Bodies of the Company 3 ARTICLE III The Board 4 ARTICLE IV Chairman and the Vice-Chairman 8 ARTICLE V Board Committees 9 ARTICLE VI Executive Officers of the Company and the Group 1
Read more →ALCAlcon s NEVANAC Suspension Receives FDA Approval for Treatment of Pain and Inflammation Associated with Cataract Surgery
Alcon s NEVANAC Suspension Receives FDA Approval for Treatment of Pain and Inflammation Associated with Cataract Surgery FORT WORTH, Texas - August 23, 2005 - Alcon, Inc. (NYSE: ACL) announced today that the U.S. Food and Drug Administration (FDA) has approved its new drug appli
Read more →ALCAlcon s Second Quarter Sales Increase 12.8 Percent
Alcon s Second Quarter Sales Increase 12.8 Percent HUNENBERG, Switzerland July 27, 2005 Alcon, Inc. (NYSE:ACL) reported global sales of $1,172.0 million for the second quarter of 2005, an increase of 12.8 percent over global sales in the second quarter of 2004, or 10.1 percent e
Read more →ALCAlcon Receives Approvable Letter from FDA for RETAANE Suspension
Alcon Receives Approvable Letter from FDA for RETAANE Suspension FORT WORTH, Texas May 24, 2005 Alcon, Inc. (NYSE:ACL) announced today that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for its New Drug Application (NDA) for RETAANE 15 mg (anecortav
Read more →ALCCMS Ruling Provides Medicare Patients Access to Alcon s AcrySof ReSTOR
CMS Ruling Provides Medicare Patients Access to Alcon s AcrySof ReSTOR IOL FORT WORTH, Texas May 10, 2005 Alcon, Inc. (NYSE:ACL) announced today that the Centers for Medicare and Medicaid Services (CMS) clarified its payment rules to present Medicare beneficiaries with the choic
Read more →ALCAlcon Will Challenge Verdict in Patent Case
Alcon Will Challenge Verdict in Patent Case FORT WORTH, Texas - May 6, 2005 - Alcon, Inc. (NYSE:ACL) announced today that a jury in the U.S. District Court in Delaware rendered a verdict that Alcon infringed Advanced Medical Optics Inc. s (NYSE: AVO) U.S. Patent Nos. 5,700,240 a
Read more →ALCAlcon, Inc
Alcon, Inc
Read more →ALCAlcon Shareholders Approve Dividend and Elect Board Members Cary Rayment Named Chairman of the Board of Directors
Alcon Shareholders Approve Dividend and Elect Board Members Cary Rayment Named Chairman of the Board of Directors HUNENNBERG, Switzerland - May 3, 2005 - Alcon, Inc., (NYSE: ACL) announced the following items were approved by shareholders at the company s Annual General Meeting
Read more →ALCAlcon Launches AcrySof ReSTOR Apodized Diffractive IOL Revolutionary Apodized Diffractive Technology Provides Highest Level of Freedom from Glasses
Alcon Launches AcrySof ReSTOR Apodized Diffractive IOL Revolutionary Apodized Diffractive Technology Provides Highest Level of Freedom from Glasses FORT WORTH, Texas - April 25, 2005 - Alcon, Inc., (NYSE: ACL) announced the launch of the AcrySof ReSTOR Intraocular Lens (IOL) at
Read more →ALCAlcon s First Quarter Earnings Rise 30.6 Percent on 11.1 Percent Sales Growth
Alcon s First Quarter Earnings Rise 30.6 Percent on 11.1 Percent Sales Growth HUNENBERG, Switzerland April 21, 2005 Alcon, Inc. (NYSE:ACL) reported global sales of $1,070.5 million for the first quarter of 2005, an increase of 11.1 percent over global sales in the first quarter
Read more →ALCFor release (
For release (April 17, 2005 at 8:00 p.m. ET) NEVANAC Suspension Clinical Data Presented at Eye Care Conference FDA Accepts NDA for Priority Review WASHINGTON, DC - April 17, 2005 - Alcon, Inc. (NYSE: ACL) presented Phase III clinical data on its investigational new drug, NEVAN
Read more →ALCFDA Approves Alcon s AcrySof ReSTOR Intraocular Lens
FDA Approves Alcon s AcrySof ReSTOR Intraocular Lens FORT WORTH, Texas March 23, 2005 Alcon, Inc. (NYSE: ACL), announced today that the U.S. Food and Drug Administration (FDA) has granted approval of its AcrySof ReSTOR intraocular lens (IOL) for cataract patients with and withou
Read more →ALCAlcon For immediate release New RETAANE Clinical Study Data Reported at Macula Society Meeting
New RETAANE Clinical Study Data Reported at Macula Society Meeting FORT WORTH, Texas February 25, 2005 Alcon, Inc. (NYSE:ACL) reported the results of a clinical pharmacokinetic (PK) study evaluating the effectiveness of a counter pressure device (CPD) it developed to control
Read more →ALCAlcon For immediate release Alcon s Fourth Quarter Earnings Rise 39.9 Percent on 11.9 Percent Sales Growth
Alcon s Fourth Quarter Earnings Rise 39.9 Percent on 11.9 Percent Sales Growth HUNENBERG, Switzerland February 9, 2005 Alcon, Inc. (NYSE:ACL) reported global sales of $952.7 million for the fourth quarter of 2004, an increase of 11.9 percent over global sales in the fourth quar
Read more →ALCAlcon For immediate release Alcon Submits RETAANE Drug Applications to U.S. and European Regulatory Authorities
Alcon Submits RETAANE Drug Applications to U.S. and European Regulatory Authorities FORT WORTH, Texas December 16, 2004 Alcon, Inc. (NYSE:ACL) has submitted the third and final reviewable unit of its New Drug Application (NDA) for RETAANE 15 mg (anecortave acetate for depot sus
Read more →ALCAlcon, Inc. Slides used for Alcon, Inc. s Clinical Information presentation at the American Academy of Ophthalmologists meeting on
Slides used for Alcon, Inc. s Clinical Information presentation at the American Academy of Ophthalmologists meeting on October 22, 2004.
Read more →ALCAlcon, Inc. Slides used for Alcon, Inc. s Company Information presentation at the American Academy of Ophthalmologists meeting on
Slides used for Alcon, Inc. s Company Information presentation at the American Academy of Ophthalmologists meeting on October 22, 2004.
Read more →ALCAlcon For immediate release Alcon Presents More Retaane Clinical Information to Retinal Specialists New Orleans, Louisiana
Alcon Presents More Retaane Clinical Information to Retinal Specialists New Orleans, Louisiana October 21, 2004 Alcon, Inc. (NYSE:ACL) presented more details about its Phase III clinical study comparing Retaane 15 mg Depot (anecortave acetate for depot suspension) to Visudyne ph
Read more →ALCAlcon For immediate release Alcon s Third Quarter Earnings Rise 26.9 Percent on 16.5 Percent Sales Growth H
Alcon s Third Quarter Earnings Rise 26.9 Percent on 16.5 Percent Sales Growth H NENBERG, Switzerland, October 20, 2004 Alcon, Inc. (NYSE: ACL) reported global sales of $958.1 million for the third quarter of 2004, an increase of 16.5 percent over global sales in the third quart
Read more →ALCAlcon For immediate release Alcon Announces Anecortave Acetate Clinical Results H nenberg, Switzerland
Alcon Announces Anecortave Acetate Clinical Results H nenberg, Switzerland October 13, 2004 Alcon, Inc. (NYSE:ACL) has completed an initial analysis of the one-year data from its comparative study of anecortave acetate (15 mg for depot suspension) versus Visudyne photodynamic th
Read more →ALCALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS September 2004 ALCON, INC.BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS Table of Contents Article I Authority 3 Article II Executive Bodies of the Company 3 Artic
ALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS ALCON, INC.BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS Article I Authority 3 Article II Executive Bodies of the Company 3 Article III The Board 4 Article IV Chairman and the Vice-Chairman 8 Article V Board C
Read more →ALCAlcon Alcon Receives Approvable Letter for EXTRAVAN Fort Worth, TX
Alcon Receives Approvable Letter for EXTRAVAN Fort Worth, TX, September 17, 2004 Alcon, Inc. (NYSE:ACL) today announced that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for EXTRAVAN ophthalmic solution for the treatment of glaucoma. EXTRAVAN solut
Read more →ALCAlcon Statement Re: The Times Of London Article Of August 28, 2004
Alcon Statement Re: The Times Of London Article Of August 28, 2004 The article appearing in the August 28, 2004 edition of The Times of London regarding Alcon and its LADARVision 4000 is based on allegations that are false and inaccurate. This article is based on the invalid c
Read more →ALCAlcon For immediate release Alcon s Second Quarter Earnings Rise 67.9 Percent on 12.3 Percent Sales Growth
Alcon s Second Quarter Earnings Rise 67.9 Percent on 12.3 Percent Sales Growth HUNENBERG, Switzerland July 28, 2004 Alcon, Inc. (NYSE: ACL) reported global sales of $1,039.2 million for the second quarter of 2004, an increase of 12.3 percent over global sales in the second qua
Read more →ALCAlcon For immediate release Alcon Provides Estimate of Second Quarter Earnings H nenberg, Switzerland
Alcon Provides Estimate of Second Quarter Earnings H nenberg, Switzerland July 13, 2004 Alcon (NYSE:ACL) management announced today it expects second quarter diluted earnings per share to be in the range of $0.94 to $0.96. This range includes an $0.18 per share favorable impac
Read more →ALCAlcon For immediate release Tim Sear to Retire As Alcon President, CEO Cary Rayment Elected to Fill the Posts H nenberg, Switzerland
Tim Sear to Retire As Alcon President, CEO Cary Rayment Elected to Fill the Posts H nenberg, Switzerland July 12, 2004 Alcon, Inc. (NYSE:ACL) Chairman, President and Chief Executive Officer Tim Sear announced today that he will retire as President and Chief Executive Officer e
Read more →ALCAlcon For immediate release RETAANE 15mg Depot Clinical Update Presented at Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting
RETAANE 15mg Depot Clinical Update Presented at Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting FORT WORTH, Texas May 20, 2004 Alcon, Inc. (NYSE:ACL) reviewed data on the RETAANE 15 mg (anecortave acetate for depot suspension) phase II/III study an
Read more →ALCAlcon For immediate release Alcon Receives FDA Approval for a SupplementalList of Susceptible Pathogens for VIGAMOX Ophthalmic Solution Fort Worth, TX
Alcon Receives FDA Approval for a SupplementalList of Susceptible Pathogens for VIGAMOX Ophthalmic Solution Fort Worth, TX, April 26, 2004 Alcon, Inc. (NYSE:ACL) announced today that it has received U.S. Food and Drug Administration (FDA) approval to add a supplemental list of
Read more →ALCGUARANTEE FEE AND COMMERCIAL PAPER PROGRAM SERVICES AGREEMENT This Agreement among NESTL S.A., 55 avenue Nestl , Ch-1800 Vevey, Switzerland ( Nestl ), ALCON, INC., Bosch 69, P.O. Box 62, CH-6331 Hunenberg, Switzerland (
FEE AND COMMERCIAL PAPER PROGRAM SERVICES AGREEMENT This Agreement among NESTL S.A., 55 avenue Nestl , Ch-1800 Vevey, Switzerland ( Nestl ), ALCON, INC., Bosch 69, P.O. Box 62, CH-6331 Hunenberg, Switzerland ( AI ) and ALCON CAPITAL CORPORATION, 6201 South Freeway, Fort Worth,
Read more →ALCAlcon For immediate release Alcon s First Quarter EarningsRise 46.7 Percent on19.4 Percent Sales Growth
Alcon s First Quarter EarningsRise 46.7 Percent on19.4 Percent Sales Growth HUNENBERG, Switzerland April 20, 2004 Alcon, Inc. (NYSE: ACL) reported global sales of $963.6 million for the first quarter of 2004, an increase of 19.4 percent over global sales in the first quarter o
Read more →ALCAlcon For immediate release Alcon Will Not Appeal Court s Decision H nenberg, Switzerland
Alcon Will Not Appeal Switzerland March 31, 2004 On March 26, 2004, the Court of Appeals for the Federal Circuit in Washington, D.C. affirmed the District Court s December 20, 2002 post-trial order overturning a jury s determination that Nidek was infringing Summit Technology
Read more →ALCAlcon For Immediate Release Alcon Releases Clinical Results on New Nasal Allergy Spray Fort Worth, TX
Alcon Releases Clinical Results on New Nasal Allergy Spray Fort Worth, TX, March 21, 2004 Alcon announced today results from a Phase III clinical trial demonstrating that olopatadine nasal spray, a nasal formulation of its market leading ophthalmic anti-allergy product, Patano
Read more →ALCPRENTATION COWEN HEALTHCARE CONFERENCE 3/10/04 Alcon, Inc Alcon, Inc. Slides to be used at the S.G. Cowen Healthcare Conference
PRENTATION COWEN HEALTHCARE CONFERENCE 3/10/04 Alcon, Inc Alcon, Inc. Slides to be used at the S.G. Cowen Healthcare Conference March 10, 2004
Read more →ALCAlcon For immediate release: Alcon Reports Additional Clinical Data on Potential New Glaucoma Drug Fort Worth, Texas
For immediate release: Alcon Reports Additional Clinical Data on Potential New Glaucoma Drug Fort Worth, Texas March 7, 2004 Three-month data from several Phase III clinical trials on Travatan/Timolol Fixed Combination (TTFC), Alcon s investigational new drug to treat glaucom
Read more →ALCQ4 2003 WEBCAST SLIDES Alcon, Inc Alcon, Inc. 2003 Operating Results Webcast Slides
Q4 2003 WEBCAST SLIDES Alcon, Inc Alcon, Inc. 2003 Operating Results Webcast Slides
Read more →ALCALCON Q4 2004 OPERATING RESULTS PRESS RELEASE Alcon For Immediate Release Alcon s Fourth Quarter Sales Grow 13.7 Percent
Sales Grow 13.7 Percent HUNENBERG, Switzerland February 11, 2004 Alcon, Inc. (NYSE: ACL) reported global sales of $851.7 million for the fourth quarter of 2003, an increase of 13.7 percent over global sales in the fourth quarter of 2002, or 7.8 percent excluding the impact of
Read more →ALCAlcon For immediate release Alcon Views AMO Patent Lawsuit as Meritless Fort Worth, Texas
Alcon Views AMO Patent Lawsuit as Meritless Fort Worth, Texas December 16, 2003 On December 3, 2003, Advanced Medical Optics (AMO) filed a complaint against Alcon Laboratories, Inc. in the U.S. District Court for the District of Delaware, which alleges patent infringement as
Read more →ALCAlcon For immediate release New Gallup Poll Shows LASIK Fears Remain That Recent Technological Advances Address Most People Know Little About the Procedure, Fail to Talk to Doctors Anaheim, CA
New Gallup Poll Shows LASIK Fears Remain That Recent Technological Advances Address Most People Know Little About Procedure, Fail to Talk to Doctors Anaheim, CA November 17, 2003 Results of a new Gallup poll being reported here this week at the Annual Meeting of the American
Read more →ALCAlcon FOR IMMEDIATE RELEASE Alcon to Initiate New Anecortave Acetate Clinical Trials for Age-Related Macular Degeneration Studies Will Assess Effectiveness of Investigational Therapyin Slowing Progression from Dry to Wet
Alcon to Initiate New Anecortave Acetate Clinical Trials for Age-Related Macular Degeneration Effectiveness of Investigational Therapyin Slowing Progression from Dry to Wet Form Fort Worth, Texas November 13, 2003 Alcon, Inc. (NYSE:ACL) will initiate two new phase III studie
Read more →ALCAlcon For immediate release Alcon, Inc. Subsidiary Announces Closing onSale of Madrid, Spain Manufacturing Facility
Alcon, Inc. Subsidiary Announces Closing onSale of Madrid, Spain Manufacturing Facility HUNENBERG, Switzerland November 6, 2003 Alcon, Inc. s (NYSE:ACL) wholly owned subsidiary, Alcon CUS , S.A., today completed the sale of its contact lens care solutions manufacturing faci
Read more →ALCALCON, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Earnings (Unaudited) (USD in millions, except share and per share data)
Third-Quarter Earnings Rise 22.4 Percent as Sales Increase 10.6 Percent Switzerland, October 22, 2003 Alcon, Inc. (NYSE:ACL) reported global sales of $822.7 million for the third quarter of 2003, an increase of 10.6 percent over global sales in the third quarter of 2002, or 7
Read more →ALCAlcon For Immediate Release Alcon Affiliate Receives FDA Approvalof Generic Glaucoma Medication Fort Worth, Texas
Alcon Affiliate Receives Generic Glaucoma Medication Worth, Texas Sept. 16, 2003 The U.S. Food and Drug Administration today approved Falcon Pharmaceuticals, Ltd. s (Falcon) generic brimonidine tartrate ophthalmic solution 0.2% (brimonidine). Falcon is an affiliate of Alcon,
Read more →ALCAnecortave Acetate Demonstrates Significant Long-Term Efficacy in Wet Age-Related Macular Degeneration Patients o New two-year data reveal prevention of vision loss and inhibition of lesion growth F
Anecortave Acetate Demonstrates Significant Long-Term Efficacy in Wet Age-Related Macular Degeneration Patients o New two-year data reveal prevention of vision loss and inhibition of lesion growth Fort Worth, Texas August 18, 2003 Alcon, Inc. (NYSE: ACL) reported today that lo
Read more →ALCAlcon, Inc. Analyst Conference Call 7/31/03 Presentation The following slides were provided as part of the Alcon, Inc. Analyst Conference Call on
Alcon, Inc. Analyst Conference Call 7/31/03 Presentation The following slides were provided as part of the Alcon, Inc. Analyst Conference Call on July 31, 2003.
Read more →ALCAlcon Alcon, Inc. B sch 69 P.O Box 62 6331 H nenberg, Switzerland For Immediate Release Alcon Reports Strong Second Quarter and Six Month 2003 Results o Second Quarter Global Sales Increased 14.3% o Second Quarter Net Ea
6331 H nenberg, Switzerland Alcon Reports Strong Second Quarter and Six Month 2003 Results o Second Quarter Global Sales Increased 14.3% o Second Quarter Net Earnings Rose 9.5% H NENBERG, Switzerland, July 30, 2003. Alcon, Inc. (NYSE: ACL) reported sales of $925.4 million
Read more →ALCA For immediate release Alcon Receives FDA Approval for Novel Combination Ear Infection Treatment
Alcon Receives FDA Approval for Novel Combination Ear Infection Treatment FORT WORTH, Texas - July 21, 2003 - Alcon, Inc. (NYSE:ACL) has received approval from the U.S. Food & Drug Administration to market Ciprodex Otic for topical treatment of a middle ear infection known as a
Read more →ALCAlcon For immediate release Alcon, Inc. Subsidiary Announces Agreement toSell Madrid, Spain Manufacturing Facility
Alcon, Inc. Subsidiary Announces Agreement toSell Madrid, Spain Manufacturing Facility HUNENBERG, Switzerland, July 17, 2003, Alcon Inc. s (NYSE: ACL) wholly owned subsidiary, Alcon CUS , S.A., announced today that it has entered into an agreement to sell its contact lens ca
Read more →ALCA For Immediate Release Alcon Announces FDA Approval of its AcrySof Natural Single-Piece IOL Earns FDA Approval for Sale in U.S. Fort Worth, Texas
Alcon Announces FDA Approval of its AcrySof Natural Single-Piece IOL Earns FDA Approval for Sale in U.S. Fort Worth, Texas - June 30, 2003 - The U.S. Food and Drug Administration (FDA) approved the AcrySof Natural Single-Piece intraocular lens, Alcon's newest addition to its l
Read more →ALCA Alcon, Inc. B sch 69 P.O. Box 62 6331 H nenberg, Switzerland For immediate release Thomas G. Plaskett Elected to Alcon, Inc. Board of Directors
6331 H nenberg, Switzerland Thomas G. Plaskett Elected to Alcon, Inc. Board of Directors HUNENBERG, Switzerland - May 20, 2003 - The shareholders of Alcon, Inc. (NYSE: ACL) today elected Thomas G. Plaskett to the company's Board of Directors at its shareholder meeting in Zug,
Read more →ALCA For immediate Release Alcon Presents New Study Results on Patanol Solution at ARVO Meeting
Alcon Presents New Study Results on Patanol Solution at ARVO Meeting FORT WORTH, Texas - May 7, 2003 - Alcon, Inc. (NYSE:ACL) presented results of two new studies involving Patanol (olopatadine hydrochloride ophthalmic solution 0.1%) at the May 4-9 meeting of the Association fo
Read more →ALCInvitation to the Annual General Meeting of Alcon, Inc. Tuesday
Invitation to the Annual General Meeting of Alcon, Inc. Tuesday, May 20, 2003, 2:00 p.m. (doors open 1:00 p.m.) Congress Center Metalli at the Parkhotel Zug, CH-6304 Zug, Switzerland phone: + 41 41 727 48 48 fax: + 41 41 727 48 49 Agenda 1. Approval of the 2002 Annual Report
Read more →ALCAlcon, Inc. 2002 Annual Report Part 1 of 3
Alcon, Inc. 2002 Annual Report Part 1 of 3
Read more →ALCALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS October March 20032 ALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS Table of Contents Article I Authority * Article II Executive Bodies of the Company *
ORGANIZATIONAL REGULATIONS ORGANIZATIONAL REGULATIONS Article I Authority * Article II Executive Bodies of the Company * Article III The Board * Article IV Chairman and the Vice-Chairman * Article V Board Committees * Article VI Executive Officers of the Company and the Gr
Read more →ALCAlcon, Inc.
Alcon, Inc. Analyst Conference Call 4/23/03 Presentation The following slides were provided as part of the Alcon, Inc. Analyst Conference Call on April 23, 2003.
Read more →ALCA Alcon, Inc. B sch 69 P.O. Box 62 6331 H nenberg, Switzerland For immediate release Alcon's First Quarter Net Earnings Rose 38.5% on 14.2% Sales Increase
6331 H nenberg, Switzerland Alcon's First Quarter Net Earnings Rose 38.5% on 14.2% Sales Increase HUNENBERG, Switzerland - April 22, 2003 - Alcon, Inc. (NYSE: ACL) reported global sales of $807.1 million for the first quarter of 2003, an increase of 14.2 percent over global sa
Read more →ALCA For Immediate Release Alcon's Newest Antibiotic, VIGAMOX Ophthalmic Solution, Proves Safe and Effective in Adults and Children Fort Worth, Texas
Alcon's Newest Antibiotic, VIGAMOX Ophthalmic Solution, Proves Safe and Effective in Adults and Children Fort Worth, Texas - April 16, 2003 - Alcon, Inc. (NYSE: ACL) announced today that it received approval from the U.S. Food and Drug Administration (FDA) of its newest antibio
Read more →ALCAlcon Introduces INFINITI Vision System, a Revolutionary Cataract Removal System FORT WORTH, Texas, April 14 - The newest technology in cataract removal devices debuted at the Alcon (NYSE:ACL) exhib
Alcon Introduces INFINITI Vision System, a Revolutionary Cataract Removal System FORT WORTH, Texas, April 14 - The newest technology in cataract removal devices debuted at the Alcon (NYSE:ACL) exhibit during the American Society of Cataract and Refractive Surgery (ASCRS) Sympos
Read more →ALCALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS October 2002 2 | 18 ALCON, INC. BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS Table of Contents Article I Authority ..............................................
BOARD OF DIRECTORS ORGANIZATIONAL REGULATIONS ORGANIZATIONAL REGULATIONS ORGANIZATIONAL REGULATIONS Article I Authority .........................................................3 Article II Executive Bodies of the Company...................................3 Article III The B
Read more →ALCArticles of Association of Alcon, Inc. as of
Articles of Association of Alcon, Inc. as of July 23, 2002 SECTION 1: NAME, PLACE OF INCORPORATION, PURPOSE AND DURATION Name, Place of Incorporation Under the name Alcon, Inc. there exists a corporation with its place of incorporation in Hunenberg, Canton of Zug, Switzerland
Read more →ALCCORPORATE REPORT
CORPORATE REPORT
Read more →ALCA Alcon, Inc. Bosch 69 P.O. Box 62 6331 Hunenberg, Switzerland For release
6331 Hunenberg, Switzerland For release June 10, 2002 Alcon Laboratories, Inc. CFO to Retire June 30, Replacement Named Effective July 1 Hunenberg, Switzerland - June 10, 2002 - Alcon, Inc. (NYSE: ACL) announced today that Charles E. Miller, Sr., senior vice president and ch
Read more →ALC1.txt PRESS RELEASE [Alcon logo] Alcon Research, Ltd. 6201 South Freeway Fort Worth, 76134 For immediate release Alcon Releases Results for Anecortave Acetate Therapy for Wet Age-Related Macular Degeneration Fort Worth,
Alcon Research, Ltd. Alcon Releases Results for Anecortave Acetate Therapy for Wet Age-Related Macular Degeneration Fort Worth, TX, May 5, 2002 - Alcon Research, Ltd. reported preliminary results today from its Phase II clinical trials demonstrating that anecortave acetate,
Read more →ALC1.txt PRESS RELEASE Alcon, Inc. Bosch 69 P.O. Box 62 6331 Hunenberg, Switzerland For immediate release ALCON LEADS THE INDUSTRY WITH PMA FILING FOR CUSTOM LASIK SURGERY FORT WORTH, TEXAS - Alcon, Inc. (NYSE: ACL) announc
6331 Hunenberg, Switzerland ALCON LEADS THE INDUSTRY WITH PMA FILING FOR CUSTOM LASIK SURGERY FORT WORTH, TEXAS - Alcon, Inc. (NYSE: ACL) announced today that the U.S. Food and Drug Administration (FDA) has accepted its custom wavefront-guided laser eye surgery Pre-Market Ap
Read more →Competitive Position
How ALC ranks across every disease it competes inCompetitive Position is a premium feature
See how ALC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial